✦ LIBER ✦

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

✍ Scribed by Hagan, Liesl M.; Sulkowski, Mark S.; Schinazi, Raymond F.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of sofosbuvi

✍ Saab, S.; Gordon, S. C.; Park, H.; Sulkowski, M.; Ahmed, A.; Younossi, Z. 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

Simeprevir plus sofosbuvir, with or with

✍ Lawitz, Eric; Sulkowski, Mark S; Ghalib, Reem; Rodriguez-Torres, Maribel; Younos 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 555 KB

652 Meta-Analysis: Sustained Virologic R

✍ Nguyen, Nghia; McCormack, Shelley A.; Yee, Brittany E.; Vutien, Philip; Nguyen, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 585 KB

Cost Effectiveness Analysis of Boceprevi

✍ Athanasakis, K.; Karampli, E.; Retsa, M.P.; Theodoropoulou, T.; Kyriopoulos, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Boceprevir versus placebo with pegylated

✍ Sulkowski, Mark; Pol, Stanislas; Mallolas, Josep; Fainboim, Hugo; Cooper, Curtis 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 333 KB

PIN42 The Cost-Effectiveness of Telaprev

✍ Curtis, S.; Cure, S.; Bianic, F.; Gavart, S.; Dearden, L.; Fleischmann, J.; Ouwe 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB